The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
COCIS individual patient data (IPD) meta-analysis: Carboplatin- or cisplatin-based chemotherapy (CT) as first-line treatment of small cell lung cancer (SCLC).
A. Rossi
No relevant relationships to disclose
M. Di Maio
No relevant relationships to disclose
P. Chiodini
No relevant relationships to disclose
R. Rudd
No relevant relationships to disclose
H. Okamoto
No relevant relationships to disclose
D. Skarlos
No relevant relationships to disclose
M. Frueh
No relevant relationships to disclose
W. Qian
No relevant relationships to disclose
T. Tamura
Honoraria - Bristol-Myers Squibb
E. Samantas
No relevant relationships to disclose
T. Shibata
No relevant relationships to disclose
F. Perrone
No relevant relationships to disclose
C. Gallo
No relevant relationships to disclose
C. Gridelli
No relevant relationships to disclose
O. Martelli
No relevant relationships to disclose
S. M. Lee
No relevant relationships to disclose